{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:51:37Z","timestamp":1782449497658,"version":"3.54.5"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare the effectiveness, safety, and tolerability of adjuvant trastuzumab plus pertuzumab (HP) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with residual invasive disease after neoadjuvant therapy, and to perform exploratory analyses of outcomes in clinically favorable subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Patients with HER2-positive breast cancer and residual invasive disease after NAT, enrolled between 2020 and 2024, were included. Propensity score matching (1:1) was applied to adjust for baseline characteristic differences. Kaplan-Meier survival analysis and Cox proportional hazards models were used to compare survival outcomes (iDFS, RFS, OS) between the two groups. Additionally, the incidence of adverse events and treatment adherence were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 272 patients were analyzed, with 134 remaining after propensity score matching. After a median follow-up of 37.7 months, no statistically significant differences in short-term survival outcomes were detected between the two groups. Grade 3 or higher adverse events occurred more frequently in the T-DM1 group, particularly thrombocytopenia. Treatment interruption or regimen modification occurred in 22.7% of patients in the T-DM1 group and 2.2% in the HP group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In HER2-positive breast cancer patients with residual invasive disease after NAT, no statistically significant difference in short-term recurrence or survival outcomes was detected between adjuvant HP and T-DM1, while HP was associated with a more favorable safety and tolerability profile. These findings should be interpreted as complementary real-world evidence in the contemporary dual-blockade era and as hypothesis-generating support for future risk-adapted adjuvant strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1852055","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:39:36Z","timestamp":1782448776000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhenghua","family":"Liu","sequence":"first","affiliation":[{"name":"Breast Disease Center, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Breast Disease Center, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Gai","sequence":"additional","affiliation":[{"name":"Breast Disease Center, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[{"name":"Breast Disease Center, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Yi","sequence":"additional","affiliation":[{"name":"Breast Disease Center, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Liu","sequence":"additional","affiliation":[{"name":"Breast Disease Center, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Breast Disease Center, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jnci\/djad179","article-title":"Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer","volume":"116","author":"Dieci","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122927","article-title":"Brain metastases in HER2-positive breast cancer: current and novel treatment strategies","volume":"13","author":"Garcia-Alvarez","year":"2021","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2023.03.007","article-title":"Risk of recurrence in patients with HER2+ early-stage breast cancer: literature analysis of patient and disease characteristics","volume":"23","author":"O'Shaughnessy","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100045","article-title":"Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System","volume":"4","author":"Jourdain","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13071873","article-title":"Hormone receptor-positive\/HER2-positive breast cancer: hormone therapy and anti-HER2 treatment: an update on treatment strategies","volume":"13","author":"Tommasi","year":"2024","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102529","article-title":"Optimizing treatment for HER2-positive HR-positive breast cancer","volume":"115","author":"Debien","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju152","article-title":"Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer","volume":"106","author":"Prat","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.7304","article-title":"Tumor intrinsic subtypes and gene expression signatures in early-stage ERBB2\/HER2-positive breast cancer: a pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials","volume":"10","author":"Fernandez-Martinez","year":"2024","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2022.08.012","article-title":"Residual disease burden after neoadjuvant therapy among US patients with high-risk HER2-positive early-stage breast cancer: a population effectiveness model","volume":"22","author":"Hendrix","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.012","article-title":"Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer","volume":"34","author":"Villacampa","year":"2023","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103987","article-title":"HER2DX genomic test in early-stage HER2-positive breast cancer","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9585","DOI":"10.1038\/s41467-025-65599-x","article-title":"HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab +\/- chemotherapy","volume":"16","author":"Nozawa","year":"2025","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0936","article-title":"Heterogeneous HER2 amplification-a new clinical category of HER2-positive breast cancer","volume":"11","author":"Okines","year":"2021","journal-title":"Cancer Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176454","article-title":"HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial","volume":"134","author":"Li","year":"2024","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41523-024-00636-4","article-title":"Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade","volume":"10","author":"Liefaard","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101795","article-title":"Treatment-related adverse events associated with HER2-targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"55","author":"Fu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D'Arienzo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000480492","article-title":"Adverse events of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive breast cancer patients","volume":"12","author":"Kowalczyk","year":"2017","journal-title":"Breast Care (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41523-023-00533-2","article-title":"Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer","volume":"9","author":"Pegram","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.02.006","article-title":"Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors","volume":"29","author":"Goel","year":"2016","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1852055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:39:50Z","timestamp":1782448790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1852055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1852055"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1852055","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1852055"}}